Login to Your Account

Fedratinib may make renewed Impact after Sanofi pull-plug move

By Randy Osborne
Staff Writer

Thursday, October 26, 2017

In 2010, when Sanofi SA signed a potential $560 million deal to get its hands on JAK2 inhibitor fedratinib (then known as TG-101348) via the buyout of Targegen Inc., the latter's director of research, John Hood, had high hopes for patients with myelofibrosis and polycythemia vera.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription